B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence

Jonathan C. Routh, Richard A. Ashley, Thomas J. Sebo, Christine M. Lohse, Douglas A. Husmann, Stephen A. Kramer, Eugene D Kwon

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: Despite tremendous gains in improving prognosis, 10% of patients with Wilms tumor will ultimately experience disease recurrence. The identification of novel prognostic markers and tumor associated targets for patients at risk could enable clinicians to treat recurrences more aggressively and, thus, optimize outcomes. We have previously shown that tumor expression of the T cell coregulatory ligand B7-H1 portends a poor prognosis for adults with renal cell carcinoma and represents a promising target to improve therapy. We hypothesize that this finding may be true for Wilms tumor. Materials and Methods: We identified 81 patients with Wilms tumor treated at 1 institution between 1968 and 2004. Histopathological features, including Wilms tumor B7-H1 expression, were correlated with clinical observations and outcome. Results: Tumor recurrences were noted in 22% of patients with Wilms tumor and 14% died. B7-H1 was expressed in 11 tumors (14%) and was more likely to occur in anaplastic Wilms tumor (p = 0.03). Tumor B7-H1 expression was associated with a 2.7-fold increased risk of recurrence, although this difference did not achieve statistical significance (p = 0.06). However, in favorable histology tumors B7-H1 expression was associated with a 3.7-fold increased risk of recurrence (p = 0.03). Conclusions: B7-H1 is expressed by Wilms tumor, correlates with tumor biology and is associated with an increased risk of recurrence in patients with favorable histology tumors. B7-H1 may prove useful in identifying high risk patients who could benefit from more aggressive initial treatment regimens, and may represent a promising therapeutic target. Multi-institutional studies to elucidate the role of B7-H1 in the treatment of Wilms tumor are warranted.

Original languageEnglish (US)
Pages (from-to)1954-1960
Number of pages7
JournalJournal of Urology
Volume179
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Wilms Tumor
Recurrence
Neoplasms
Histology
Therapeutics
Tumor Biomarkers
Renal Cell Carcinoma
Ligands
T-Lymphocytes

Keywords

  • biological markers
  • kidney neoplasms
  • prognosis
  • T-lymphocytes
  • Wilms tumor

ASJC Scopus subject areas

  • Urology

Cite this

Routh, J. C., Ashley, R. A., Sebo, T. J., Lohse, C. M., Husmann, D. A., Kramer, S. A., & Kwon, E. D. (2008). B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence. Journal of Urology, 179(5), 1954-1960. https://doi.org/10.1016/j.juro.2008.01.056

B7-H1 Expression in Wilms Tumor : Correlation With Tumor Biology and Disease Recurrence. / Routh, Jonathan C.; Ashley, Richard A.; Sebo, Thomas J.; Lohse, Christine M.; Husmann, Douglas A.; Kramer, Stephen A.; Kwon, Eugene D.

In: Journal of Urology, Vol. 179, No. 5, 05.2008, p. 1954-1960.

Research output: Contribution to journalArticle

Routh, JC, Ashley, RA, Sebo, TJ, Lohse, CM, Husmann, DA, Kramer, SA & Kwon, ED 2008, 'B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence', Journal of Urology, vol. 179, no. 5, pp. 1954-1960. https://doi.org/10.1016/j.juro.2008.01.056
Routh JC, Ashley RA, Sebo TJ, Lohse CM, Husmann DA, Kramer SA et al. B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence. Journal of Urology. 2008 May;179(5):1954-1960. https://doi.org/10.1016/j.juro.2008.01.056
Routh, Jonathan C. ; Ashley, Richard A. ; Sebo, Thomas J. ; Lohse, Christine M. ; Husmann, Douglas A. ; Kramer, Stephen A. ; Kwon, Eugene D. / B7-H1 Expression in Wilms Tumor : Correlation With Tumor Biology and Disease Recurrence. In: Journal of Urology. 2008 ; Vol. 179, No. 5. pp. 1954-1960.
@article{5f5f256dcbd9429d9098057eb66e83e9,
title = "B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence",
abstract = "Purpose: Despite tremendous gains in improving prognosis, 10{\%} of patients with Wilms tumor will ultimately experience disease recurrence. The identification of novel prognostic markers and tumor associated targets for patients at risk could enable clinicians to treat recurrences more aggressively and, thus, optimize outcomes. We have previously shown that tumor expression of the T cell coregulatory ligand B7-H1 portends a poor prognosis for adults with renal cell carcinoma and represents a promising target to improve therapy. We hypothesize that this finding may be true for Wilms tumor. Materials and Methods: We identified 81 patients with Wilms tumor treated at 1 institution between 1968 and 2004. Histopathological features, including Wilms tumor B7-H1 expression, were correlated with clinical observations and outcome. Results: Tumor recurrences were noted in 22{\%} of patients with Wilms tumor and 14{\%} died. B7-H1 was expressed in 11 tumors (14{\%}) and was more likely to occur in anaplastic Wilms tumor (p = 0.03). Tumor B7-H1 expression was associated with a 2.7-fold increased risk of recurrence, although this difference did not achieve statistical significance (p = 0.06). However, in favorable histology tumors B7-H1 expression was associated with a 3.7-fold increased risk of recurrence (p = 0.03). Conclusions: B7-H1 is expressed by Wilms tumor, correlates with tumor biology and is associated with an increased risk of recurrence in patients with favorable histology tumors. B7-H1 may prove useful in identifying high risk patients who could benefit from more aggressive initial treatment regimens, and may represent a promising therapeutic target. Multi-institutional studies to elucidate the role of B7-H1 in the treatment of Wilms tumor are warranted.",
keywords = "biological markers, kidney neoplasms, prognosis, T-lymphocytes, Wilms tumor",
author = "Routh, {Jonathan C.} and Ashley, {Richard A.} and Sebo, {Thomas J.} and Lohse, {Christine M.} and Husmann, {Douglas A.} and Kramer, {Stephen A.} and Kwon, {Eugene D}",
year = "2008",
month = "5",
doi = "10.1016/j.juro.2008.01.056",
language = "English (US)",
volume = "179",
pages = "1954--1960",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - B7-H1 Expression in Wilms Tumor

T2 - Correlation With Tumor Biology and Disease Recurrence

AU - Routh, Jonathan C.

AU - Ashley, Richard A.

AU - Sebo, Thomas J.

AU - Lohse, Christine M.

AU - Husmann, Douglas A.

AU - Kramer, Stephen A.

AU - Kwon, Eugene D

PY - 2008/5

Y1 - 2008/5

N2 - Purpose: Despite tremendous gains in improving prognosis, 10% of patients with Wilms tumor will ultimately experience disease recurrence. The identification of novel prognostic markers and tumor associated targets for patients at risk could enable clinicians to treat recurrences more aggressively and, thus, optimize outcomes. We have previously shown that tumor expression of the T cell coregulatory ligand B7-H1 portends a poor prognosis for adults with renal cell carcinoma and represents a promising target to improve therapy. We hypothesize that this finding may be true for Wilms tumor. Materials and Methods: We identified 81 patients with Wilms tumor treated at 1 institution between 1968 and 2004. Histopathological features, including Wilms tumor B7-H1 expression, were correlated with clinical observations and outcome. Results: Tumor recurrences were noted in 22% of patients with Wilms tumor and 14% died. B7-H1 was expressed in 11 tumors (14%) and was more likely to occur in anaplastic Wilms tumor (p = 0.03). Tumor B7-H1 expression was associated with a 2.7-fold increased risk of recurrence, although this difference did not achieve statistical significance (p = 0.06). However, in favorable histology tumors B7-H1 expression was associated with a 3.7-fold increased risk of recurrence (p = 0.03). Conclusions: B7-H1 is expressed by Wilms tumor, correlates with tumor biology and is associated with an increased risk of recurrence in patients with favorable histology tumors. B7-H1 may prove useful in identifying high risk patients who could benefit from more aggressive initial treatment regimens, and may represent a promising therapeutic target. Multi-institutional studies to elucidate the role of B7-H1 in the treatment of Wilms tumor are warranted.

AB - Purpose: Despite tremendous gains in improving prognosis, 10% of patients with Wilms tumor will ultimately experience disease recurrence. The identification of novel prognostic markers and tumor associated targets for patients at risk could enable clinicians to treat recurrences more aggressively and, thus, optimize outcomes. We have previously shown that tumor expression of the T cell coregulatory ligand B7-H1 portends a poor prognosis for adults with renal cell carcinoma and represents a promising target to improve therapy. We hypothesize that this finding may be true for Wilms tumor. Materials and Methods: We identified 81 patients with Wilms tumor treated at 1 institution between 1968 and 2004. Histopathological features, including Wilms tumor B7-H1 expression, were correlated with clinical observations and outcome. Results: Tumor recurrences were noted in 22% of patients with Wilms tumor and 14% died. B7-H1 was expressed in 11 tumors (14%) and was more likely to occur in anaplastic Wilms tumor (p = 0.03). Tumor B7-H1 expression was associated with a 2.7-fold increased risk of recurrence, although this difference did not achieve statistical significance (p = 0.06). However, in favorable histology tumors B7-H1 expression was associated with a 3.7-fold increased risk of recurrence (p = 0.03). Conclusions: B7-H1 is expressed by Wilms tumor, correlates with tumor biology and is associated with an increased risk of recurrence in patients with favorable histology tumors. B7-H1 may prove useful in identifying high risk patients who could benefit from more aggressive initial treatment regimens, and may represent a promising therapeutic target. Multi-institutional studies to elucidate the role of B7-H1 in the treatment of Wilms tumor are warranted.

KW - biological markers

KW - kidney neoplasms

KW - prognosis

KW - T-lymphocytes

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=41749091806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749091806&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.01.056

DO - 10.1016/j.juro.2008.01.056

M3 - Article

C2 - 18355839

AN - SCOPUS:41749091806

VL - 179

SP - 1954

EP - 1960

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -